Last reviewed · How we verify
R-CHOP / R-HAD
R-CHOP/R-HAD is a combination chemotherapy regimen that uses rituximab (an anti-CD20 monoclonal antibody) plus alternating cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and HAD (high-dose cytarabine, doxorubicin, dexamethasone) to target B-cell lymphomas.
R-CHOP/R-HAD is a combination chemotherapy regimen that uses rituximab (an anti-CD20 monoclonal antibody) plus alternating cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and HAD (high-dose cytarabine, doxorubicin, dexamethasone) to target B-cell lymphomas. Used for Diffuse large B-cell lymphoma (DLBCL), Other aggressive B-cell non-Hodgkin lymphomas.
At a glance
| Generic name | R-CHOP / R-HAD |
|---|---|
| Also known as | rituximab, CHOP, rituximab HD AraC |
| Sponsor | The Lymphoma Academic Research Organisation |
| Drug class | Monoclonal antibody + chemotherapy combination |
| Target | CD20 (rituximab component) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Rituximab binds to CD20 antigen on B-cell surfaces, triggering antibody-dependent cellular cytotoxicity and direct apoptosis. The alternating chemotherapy cycles (CHOP and HAD) provide intensive cytotoxic activity with different mechanisms and schedules to overcome chemotherapy resistance. This combination approach is designed to improve efficacy in aggressive lymphomas, particularly in younger or fit patients who can tolerate intensive treatment.
Approved indications
- Diffuse large B-cell lymphoma (DLBCL)
- Other aggressive B-cell non-Hodgkin lymphomas
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Infection
- Cardiotoxicity (doxorubicin-related)
- Nausea/vomiting
- Mucositis
- Infusion reactions (rituximab)
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma (PHASE3)
- A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) (PHASE3)
- Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell
- R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL (PHASE3)
- A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL
- Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™ (PHASE3)
- Prospective HIV Chemotherapy Cohort Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- R-CHOP / R-HAD CI brief — competitive landscape report
- R-CHOP / R-HAD updates RSS · CI watch RSS
- The Lymphoma Academic Research Organisation portfolio CI